via Georgia State University
Treatment of SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 hours, researchers in the Institute for Biomedical Sciences at Georgia State University have discovered.
The group led by Dr. Richard Plemper, Distinguished University Professor at Georgia State, originally discovered that the drug is potent against influenza viruses.
“This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission,” said Plemper. “MK-4482/EIDD-2801 could be game-changing.”
Interrupting widespread community transmission of SARS-CoV-2 until mass vaccination is available is paramount to managing COVID-19 and mitigating the catastrophic consequences of the pandemic.
Because the drug can be taken by mouth, treatment can be started early for a potentially three-fold benefit: inhibit patients’ progress to severe disease, shorten the infectious phase to ease the emotional and socioeconomic toll of prolonged patient isolation and rapidly silence local outbreaks.
“We noted early on that MK-4482/EIDD-2801 has broad-spectrum activity against respiratory RNA viruses and that treating infected animals by mouth with the drug lowers the amount of shed viral particles by several orders of magnitude, dramatically reducing transmission,” said Plemper. “These properties made MK-4482/EIDD/2801 a powerful candidate for pharmacologic control of COVID-19.”
In the study published in Nature Microbiology, Plemper’s team repurposed MK-4482/EIDD-2801 against SARS-CoV-2 and used a ferret model to test the effect of the drug on halting virus spread.
“We believe ferrets are a relevant transmission model because they readily spread SARS-CoV-2, but mostly do not develop severe disease, which closely resembles SARS-CoV-2 spread in young adults,” said Dr. Robert Cox, a postdoctoral fellow in the Plemper group and a co-lead author of the study.
The researchers infected ferrets with SARS-CoV-2 and initiated treatment with MK-4482/EIDD-2801 when the animals started to shed virus from the nose.
“When we co-housed those infected and then treated source animals with untreated contact ferrets in the same cage, none of the contacts became infected,” said Josef Wolf, a doctoral student in the Plemper lab and co-lead author of the study. By comparison, all contacts of source ferrets that had received placebo became infected.
If these ferret-based data translate to humans, COVID-19 patients treated with the drug could become non-infectious within 24 hours after the beginning of treatment.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- 'She's Doing Great': 109-Year Old Among Oldest To Get Vaccineon January 26, 2021 at 3:33 pm
Chick-fil-A manager helps direct long line for vaccine; Negative tests needed for anyone entering U.S.; how schools can reopen safely.
- Merck discontinues Covid-19 vaccine candidates on grounds of poor performanceon January 25, 2021 at 10:35 pm
Merck has discontinued the development of its SARS-CoV-2/Covid-19 vaccine candidates V590 and V591, after they performed poorly in phase 1 clinical trials.
- Merck ends COVID vaccine program, cites inferior immune responseson January 25, 2021 at 2:47 pm
Drugmaker Merck & Co said on Monday it would stop development of its two COVID-19 vaccines and focus pandemic research on treatments, with initial data on an experimental oral antiviral expected by ...
- Merck drops 2 potential COVID-19 vaccines after poor results in early testingon January 25, 2021 at 10:00 am
Merck is pulling the plugs on two potential COVID-19 vaccines following poor results in early-stage studies. The drugmaker said Monday it will focus instead on studying two possible treatments for the ...
- Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidateson January 25, 2021 at 3:58 am
Tax Planning Personal Finance Save for College Save for Retirement Invest in Retirement Research Mutual Funds Stocks ETFs Bonds Best Investments ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Rapid transmission of N501Y variants may be due to favorable effects on host receptor bindingon January 26, 2021 at 9:03 pm
Now, in new research posted to the preprint server bioRxiv*, scientists use an experimental structure of the Spike RBD domain co-crystallized with part of the ACE2 receptor and several in silico ...
- First case of SARS-CoV-2 variant strain detected in Alaskaon January 26, 2021 at 3:15 pm
According to a press release put out on Tuesday by the Alaska Department of Health and Social Services, the first case of the SARS-CoV-2 variant strain has been detected in Alaska after testing and ...
- Mutations in SARS-CoV-2 spike proteolytic cleavage sites may alter transmission dynamicson January 26, 2021 at 9:45 am
A study conducted by researchers at the University of Kentucky and the Washington University School of Medicine in the USA has revealed that mutations in the proteolytic cleavage site within the S2 ...
- Researchers exploring the link between sunlight and COVID transmissionon January 25, 2021 at 8:49 pm
Researchers continue to expand their understanding of the role weather elements such as ultraviolet (UV) radiation play in the spread of the pandemic.
- CDC: In-school spread of COVID-19 37% lower than community transmissionon January 25, 2021 at 4:00 pm
The spread of COVID-19 was lower in K-12 schools offering in-person instruction than in the surrounding community, according to a study released Tuesday.